Inactive

The National Cancer Institute (NCI), Center for Cancer Research (CCR), Experimental Transplantation and Immunology Branch (ETIB) identified a T-cell receptor that targets the cancer testes antigen KK-... The National Cancer Institute (NCI), Center for Cancer Research (CCR), Experimental Transplantation and Immunology Branch (ETIB) identified a T-cell receptor that targets the cancer testes antigen KK-LC-1 (also known as CT83) in a HLA-0101 restricted manner. This T-cell receptor is capable of killing tumors in-vitro and in-vivo, and furthermore has demonstrated negligible off-target effect in-vitro. This KK-LC-1 T- cell receptor will be tested in a Phase I ETIB/clinical trial. To determine if patients are eligible to be enrolled in this ETIB/NCI clinical trial, a RNAscope in-situ hybridization assay will be performed to check if patients express KK-LC-1. RNAscope is an RNA probe-based technology used to accurately identify RNA transcripts in cells. Specifically, NCI will use CT83 specific RNA probes to identify CT83 RNA transcripts in patient biopsies. Presence of more than or equal to 30% CT83 expression in the biopsies will be used for the inclusion criterion. A Bond RX machine is used to perform this RNAscope assay in an automated fashion. Previously a bond Rx machine was used to optimize CT83 RNAscope prior to starting the clinical trial. Acquiring a machine that is conducive to the RNAscope technique is critical to the success of this trial. TYPE OF ORDER This shall be issued as a Non-Severable Firm Fixed-Price Purchase Order. PRODUCT FEATURES/SALIENT CHARACTERISTICS The following salient features/characteristics are required for this equipment: Must be designed with RNAscope technique in mind to include 7 buffer washes, 2 protease treatments and single probe binding. Must provide easy access to the buffers, probes and detection systems at any time. Must accommodate Titration containers for volumes ranging from 20ul to 1ml. Must be programmable in order to adjust for the period of time the assay will be used, the volume of reagents required, and the frequency of reagent treatments to ensure flexibility of analysis and consistency of results. Must provide indicators revealing each stage of the assay process including reagent application, protocol progress monitoring and comprehensive reports. Must indicate quantity of buffers inside containers, probes and detection reagents. Must be able to hold up to 9 one-gallon containers that include a handle. Must include unique active lighting system. Must be able to operate automatically independent of manual labor. Must be able to complete the assay within 12 hours. Must dispense reagents while preserving morphology and integrity of precious tissue. Must be able to print out slide identifiers to label each separate biopsy sample. Must include scanner to identify each specific program. Must include uninterruptible power supply. A minimum 12-month manufacturer warranty must be included. Shipping/Handling costs must be included in the quote. NCI will not be responsible in the event charges are not included in the quote. Installation charges must be included in the quote. DELIVERY / INSTALLATION Contractor shall deliver the item(s) within 6 weeks after award to:Frederick, Maryland 21701. The Contractor that receives the award will be provided with the complete mailing address and point of contact. Upon award, contractor must notify the NCI Technical Point of Contact (TPOC) to schedule the delivery. Delivery address: 8560 Progress Drive (ATRF Building, Room C3002),Frederick, Maryland 21701